Medical Developments International (MVP) H2 2025 earnings summary

Executive summary

• Group revenue increased 18% year-over-year to $39.1 million, with strong growth in both Pain Management and Respiratory segments and significant improvements in margins, earnings, and cash flow.

• Margin improvements and cost reductions of approximately $4 million each drove a turnaround in EBIT and cash flow.

• Net profit after tax reached $0.1 million, reversing a prior year loss of $41.0 million, marking the first full-year net profit in several periods.

• Transitioned Penthrox distribution in France and Switzerland to experienced partners and secured HPRA approval for pediatric use in Europe, expanding the addressable market.

• Set the foundation for sustainable growth, focusing on accelerating volume growth and embedding Penthrox as a standard of care in FY26 and beyond.

Financial highlights

• Group revenue rose 18% year-over-year to $39.1 million; Pain Management revenue up 23% to $26.2 million, Respiratory up 9% to $12.9 million.

• Underlying EBIT improved by $11.6 million, reaching breakeven; reported EBIT up $33 million.

• Net profit after tax reached $0.1 million, an improvement of $41 million.

• Free cash flow improved by $12.9 million; cash at period end was $17.8 million.

• Operating cash flow improved by almost $11 million; CapEx down, supporting improved free cash flow.

Outlook and guidance

• FY26 will see increased investment in growth initiatives, particularly to drive behavioral change and embed Penthrox as standard of care.

• Expectation of softer underlying EBIT in FY26 due to upfront investment and distribution changes, but stronger long-term financial performance anticipated.

• Launch of pediatric label in Europe and further expansion in the US respiratory market are key priorities.

• Anticipate material increase in Penthrox use in UK and European ambulances in FY27 following pediatric approval.

• Modest cost increase in FY26, mainly in medical and commercial investment, estimated at around $2 million.